nodes	percent_of_prediction	percent_of_DWPC	metapath
Pethidine—CYP3A4—bone cancer	0.754	1	CbGaD
Pethidine—CYP2B6—Cisplatin—bone cancer	0.0158	0.353	CbGbCtD
Pethidine—CYP2B6—Doxorubicin—bone cancer	0.0106	0.236	CbGbCtD
Pethidine—ALB—Methotrexate—bone cancer	0.01	0.224	CbGbCtD
Pethidine—Fibrosis—Cisplatin—bone cancer	0.0055	0.056	CcSEcCtD
Pethidine—CYP2D6—Doxorubicin—bone cancer	0.00511	0.114	CbGbCtD
Pethidine—Phlebitis—Carboplatin—bone cancer	0.00451	0.046	CcSEcCtD
Pethidine—Neurotoxicity—Cisplatin—bone cancer	0.00405	0.0413	CcSEcCtD
Pethidine—CYP3A4—Doxorubicin—bone cancer	0.00325	0.0726	CbGbCtD
Pethidine—Fibrosis—Methotrexate—bone cancer	0.00302	0.0307	CcSEcCtD
Pethidine—Anuria—Methotrexate—bone cancer	0.00247	0.0251	CcSEcCtD
Pethidine—Ketobemidone—CYP3A4—bone cancer	0.00247	0.587	CrCbGaD
Pethidine—Anuria—Epirubicin—bone cancer	0.00231	0.0235	CcSEcCtD
Pethidine—Neurotoxicity—Methotrexate—bone cancer	0.00222	0.0226	CcSEcCtD
Pethidine—Anuria—Doxorubicin—bone cancer	0.00214	0.0218	CcSEcCtD
Pethidine—Neurotoxicity—Epirubicin—bone cancer	0.00208	0.0212	CcSEcCtD
Pethidine—Neurotoxicity—Doxorubicin—bone cancer	0.00193	0.0196	CcSEcCtD
Pethidine—Levomilnacipran—CYP3A4—bone cancer	0.00174	0.413	CrCbGaD
Pethidine—Phlebitis—Cisplatin—bone cancer	0.00132	0.0135	CcSEcCtD
Pethidine—Paralysis—Methotrexate—bone cancer	0.00124	0.0126	CcSEcCtD
Pethidine—Paralysis—Epirubicin—bone cancer	0.00116	0.0118	CcSEcCtD
Pethidine—Irritability—Cisplatin—bone cancer	0.00109	0.0111	CcSEcCtD
Pethidine—Paralysis—Doxorubicin—bone cancer	0.00107	0.0109	CcSEcCtD
Pethidine—Orthostatic hypotension—Cisplatin—bone cancer	0.00104	0.0106	CcSEcCtD
Pethidine—Injection site pain—Epirubicin—bone cancer	0.000988	0.0101	CcSEcCtD
Pethidine—Delirium—Epirubicin—bone cancer	0.000938	0.00955	CcSEcCtD
Pethidine—Vasodilation procedure—Epirubicin—bone cancer	0.000918	0.00935	CcSEcCtD
Pethidine—Vasodilation—Epirubicin—bone cancer	0.000918	0.00935	CcSEcCtD
Pethidine—Injection site pain—Doxorubicin—bone cancer	0.000915	0.00931	CcSEcCtD
Pethidine—Delirium—Doxorubicin—bone cancer	0.000868	0.00884	CcSEcCtD
Pethidine—Dyskinesia—Epirubicin—bone cancer	0.000859	0.00874	CcSEcCtD
Pethidine—Vasodilation procedure—Doxorubicin—bone cancer	0.00085	0.00865	CcSEcCtD
Pethidine—Vasodilation—Doxorubicin—bone cancer	0.00085	0.00865	CcSEcCtD
Pethidine—Depressed level of consciousness—Methotrexate—bone cancer	0.000833	0.00848	CcSEcCtD
Pethidine—Coordination abnormal—Epirubicin—bone cancer	0.000822	0.00837	CcSEcCtD
Pethidine—Bradycardia—Cisplatin—bone cancer	0.000803	0.00818	CcSEcCtD
Pethidine—Dyskinesia—Doxorubicin—bone cancer	0.000794	0.00809	CcSEcCtD
Pethidine—Coma—Methotrexate—bone cancer	0.000788	0.00802	CcSEcCtD
Pethidine—Visual impairment—Cisplatin—bone cancer	0.00076	0.00774	CcSEcCtD
Pethidine—Coordination abnormal—Doxorubicin—bone cancer	0.00076	0.00774	CcSEcCtD
Pethidine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—BRAF—bone cancer	0.000755	0.00764	CbGpPWpGaD
Pethidine—Coma—Epirubicin—bone cancer	0.000737	0.00751	CcSEcCtD
Pethidine—Flushing—Cisplatin—bone cancer	0.000732	0.00746	CcSEcCtD
Pethidine—CYP2C19—Xenobiotics—CYP3A4—bone cancer	0.00073	0.00738	CbGpPWpGaD
Pethidine—GRIN2B—ErbB4 signaling events—MDM2—bone cancer	0.000718	0.00727	CbGpPWpGaD
Pethidine—CYP2C19—Tamoxifen metabolism—CYP3A4—bone cancer	0.000702	0.0071	CbGpPWpGaD
Pethidine—Erythema—Cisplatin—bone cancer	0.000687	0.007	CcSEcCtD
Pethidine—Coma—Doxorubicin—bone cancer	0.000682	0.00695	CcSEcCtD
Pethidine—Phlebitis—Epirubicin—bone cancer	0.00068	0.00692	CcSEcCtD
Pethidine—CYP2D6—Xenobiotics—CYP3A4—bone cancer	0.000671	0.00679	CbGpPWpGaD
Pethidine—CYP2B6—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000663	0.00671	CbGpPWpGaD
Pethidine—Visual disturbance—Methotrexate—bone cancer	0.000661	0.00673	CcSEcCtD
Pethidine—Muscle spasms—Cisplatin—bone cancer	0.00066	0.00673	CcSEcCtD
Pethidine—GRIN1—BDNF signaling pathway—EIF2S1—bone cancer	0.000654	0.00661	CbGpPWpGaD
Pethidine—CYP2C19—Metapathway biotransformation—CYP4V2—bone cancer	0.000651	0.00658	CbGpPWpGaD
Pethidine—CYP2D6—Tamoxifen metabolism—CYP3A4—bone cancer	0.000646	0.00653	CbGpPWpGaD
Pethidine—Tremor—Cisplatin—bone cancer	0.000644	0.00655	CcSEcCtD
Pethidine—GRIN2B—BDNF signaling pathway—EIF2S1—bone cancer	0.000637	0.00645	CbGpPWpGaD
Pethidine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000632	0.00639	CbGpPWpGaD
Pethidine—Phlebitis—Doxorubicin—bone cancer	0.000629	0.00641	CcSEcCtD
Pethidine—CYP2D6—Metapathway biotransformation—CYP4V2—bone cancer	0.000599	0.00606	CbGpPWpGaD
Pethidine—Irritability—Methotrexate—bone cancer	0.000597	0.00608	CcSEcCtD
Pethidine—Convulsion—Cisplatin—bone cancer	0.000595	0.00606	CcSEcCtD
Pethidine—Mood swings—Methotrexate—bone cancer	0.000593	0.00604	CcSEcCtD
Pethidine—Anxiety—Cisplatin—bone cancer	0.000583	0.00593	CcSEcCtD
Pethidine—Affect lability—Epirubicin—bone cancer	0.000577	0.00587	CcSEcCtD
Pethidine—Oedema—Cisplatin—bone cancer	0.000561	0.00571	CcSEcCtD
Pethidine—Anaphylactic shock—Cisplatin—bone cancer	0.000561	0.00571	CcSEcCtD
Pethidine—Cardiac arrest—Epirubicin—bone cancer	0.000557	0.00567	CcSEcCtD
Pethidine—Mood swings—Epirubicin—bone cancer	0.000555	0.00565	CcSEcCtD
Pethidine—ALB—Binding and Uptake of Ligands by Scavenger Receptors—SPARC—bone cancer	0.000552	0.00559	CbGpPWpGaD
Pethidine—Tachycardia—Cisplatin—bone cancer	0.000547	0.00557	CcSEcCtD
Pethidine—Hyperhidrosis—Cisplatin—bone cancer	0.000542	0.00552	CcSEcCtD
Pethidine—Orthostatic hypotension—Epirubicin—bone cancer	0.000535	0.00545	CcSEcCtD
Pethidine—Anorexia—Cisplatin—bone cancer	0.000534	0.00544	CcSEcCtD
Pethidine—Affect lability—Doxorubicin—bone cancer	0.000533	0.00543	CcSEcCtD
Pethidine—Hypotension—Cisplatin—bone cancer	0.000524	0.00533	CcSEcCtD
Pethidine—Cardiac arrest—Doxorubicin—bone cancer	0.000515	0.00525	CcSEcCtD
Pethidine—Mood swings—Doxorubicin—bone cancer	0.000513	0.00523	CcSEcCtD
Pethidine—CYP2C19—Constitutive Androstane Receptor Pathway—CYP3A4—bone cancer	0.000501	0.00507	CbGpPWpGaD
Pethidine—Orthostatic hypotension—Doxorubicin—bone cancer	0.000495	0.00504	CcSEcCtD
Pethidine—OPRK1—G alpha (i) signalling events—GRM4—bone cancer	0.000494	0.005	CbGpPWpGaD
Pethidine—OPRK1—G alpha (i) signalling events—RGS1—bone cancer	0.000494	0.005	CbGpPWpGaD
Pethidine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000491	0.00497	CbGpPWpGaD
Pethidine—Decreased appetite—Cisplatin—bone cancer	0.000487	0.00496	CcSEcCtD
Pethidine—Drowsiness—Methotrexate—bone cancer	0.000482	0.00491	CcSEcCtD
Pethidine—Sweating—Methotrexate—bone cancer	0.000462	0.00471	CcSEcCtD
Pethidine—Feeling abnormal—Cisplatin—bone cancer	0.000462	0.0047	CcSEcCtD
Pethidine—Drowsiness—Epirubicin—bone cancer	0.000451	0.0046	CcSEcCtD
Pethidine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000436	0.00441	CbGpPWpGaD
Pethidine—Sweating—Epirubicin—bone cancer	0.000433	0.00441	CcSEcCtD
Pethidine—Drowsiness—Doxorubicin—bone cancer	0.000418	0.00425	CcSEcCtD
Pethidine—OPRM1—G alpha (i) signalling events—GRM4—bone cancer	0.000418	0.00423	CbGpPWpGaD
Pethidine—OPRM1—G alpha (i) signalling events—RGS1—bone cancer	0.000418	0.00423	CbGpPWpGaD
Pethidine—Visual impairment—Methotrexate—bone cancer	0.000417	0.00425	CcSEcCtD
Pethidine—Hypersensitivity—Cisplatin—bone cancer	0.000413	0.00421	CcSEcCtD
Pethidine—Bradycardia—Epirubicin—bone cancer	0.000413	0.0042	CcSEcCtD
Pethidine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000405	0.0041	CbGpPWpGaD
Pethidine—Asthenia—Cisplatin—bone cancer	0.000402	0.0041	CcSEcCtD
Pethidine—CYP2B6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000401	0.00406	CbGpPWpGaD
Pethidine—Sweating—Doxorubicin—bone cancer	0.0004	0.00408	CcSEcCtD
Pethidine—CYP2B6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000396	0.004	CbGpPWpGaD
Pethidine—CYP3A4—Metapathway biotransformation—CYP4V2—bone cancer	0.000391	0.00396	CbGpPWpGaD
Pethidine—Visual impairment—Epirubicin—bone cancer	0.000391	0.00398	CcSEcCtD
Pethidine—Bradycardia—Doxorubicin—bone cancer	0.000382	0.00389	CcSEcCtD
Pethidine—Erythema—Methotrexate—bone cancer	0.000377	0.00384	CcSEcCtD
Pethidine—Flushing—Epirubicin—bone cancer	0.000376	0.00383	CcSEcCtD
Pethidine—GRIN1—EPH-Ephrin signaling—MMP2—bone cancer	0.000376	0.0038	CbGpPWpGaD
Pethidine—GRIN1—Spinal Cord Injury—CDK4—bone cancer	0.000376	0.0038	CbGpPWpGaD
Pethidine—ALB—Folate Metabolism—DHFR—bone cancer	0.000369	0.00374	CbGpPWpGaD
Pethidine—GRIN2B—EPH-Ephrin signaling—MMP2—bone cancer	0.000367	0.00371	CbGpPWpGaD
Pethidine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000365	0.00369	CbGpPWpGaD
Pethidine—Visual impairment—Doxorubicin—bone cancer	0.000361	0.00368	CcSEcCtD
Pethidine—Vomiting—Cisplatin—bone cancer	0.000356	0.00363	CcSEcCtD
Pethidine—Rash—Cisplatin—bone cancer	0.000353	0.0036	CcSEcCtD
Pethidine—Dermatitis—Cisplatin—bone cancer	0.000353	0.0036	CcSEcCtD
Pethidine—Erythema—Epirubicin—bone cancer	0.000353	0.00359	CcSEcCtD
Pethidine—Flushing—Doxorubicin—bone cancer	0.000348	0.00354	CcSEcCtD
Pethidine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000339	0.00343	CbGpPWpGaD
Pethidine—Muscle spasms—Epirubicin—bone cancer	0.000339	0.00345	CcSEcCtD
Pethidine—Vertigo—Methotrexate—bone cancer	0.000339	0.00345	CcSEcCtD
Pethidine—Nausea—Cisplatin—bone cancer	0.000333	0.00339	CcSEcCtD
Pethidine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000333	0.00336	CbGpPWpGaD
Pethidine—GRIN2C—Alzheimers Disease—TP53—bone cancer	0.000331	0.00335	CbGpPWpGaD
Pethidine—SLC6A4—NRF2 pathway—TGFBR2—bone cancer	0.000328	0.00332	CbGpPWpGaD
Pethidine—SLC6A4—NRF2 pathway—GSTP1—bone cancer	0.000328	0.00332	CbGpPWpGaD
Pethidine—SLC6A4—Circadian rythm related genes—GNA11—bone cancer	0.000328	0.00331	CbGpPWpGaD
Pethidine—GRIN2C—Transmission across Chemical Synapses—BRAF—bone cancer	0.000327	0.00331	CbGpPWpGaD
Pethidine—GRIN1—Spinal Cord Injury—RB1—bone cancer	0.000327	0.00331	CbGpPWpGaD
Pethidine—Convulsion—Methotrexate—bone cancer	0.000327	0.00333	CcSEcCtD
Pethidine—Erythema—Doxorubicin—bone cancer	0.000326	0.00332	CcSEcCtD
Pethidine—SLC6A4—Circadian rythm related genes—EZH2—bone cancer	0.000326	0.0033	CbGpPWpGaD
Pethidine—CYP2B6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000325	0.00329	CbGpPWpGaD
Pethidine—Agitation—Epirubicin—bone cancer	0.000324	0.0033	CcSEcCtD
Pethidine—ALB—Platelet degranulation—SPARC—bone cancer	0.000323	0.00327	CbGpPWpGaD
Pethidine—Vertigo—Epirubicin—bone cancer	0.000317	0.00323	CcSEcCtD
Pethidine—Syncope—Epirubicin—bone cancer	0.000316	0.00322	CcSEcCtD
Pethidine—Muscle spasms—Doxorubicin—bone cancer	0.000314	0.0032	CcSEcCtD
Pethidine—Palpitations—Epirubicin—bone cancer	0.000312	0.00317	CcSEcCtD
Pethidine—Confusional state—Methotrexate—bone cancer	0.00031	0.00316	CcSEcCtD
Pethidine—Loss of consciousness—Epirubicin—bone cancer	0.00031	0.00316	CcSEcCtD
Pethidine—ALB—Response to elevated platelet cytosolic Ca2+—SPARC—bone cancer	0.000308	0.00312	CbGpPWpGaD
Pethidine—GRIN2D—Alzheimers Disease—TP53—bone cancer	0.000308	0.00311	CbGpPWpGaD
Pethidine—Anaphylactic shock—Methotrexate—bone cancer	0.000308	0.00313	CcSEcCtD
Pethidine—Convulsion—Epirubicin—bone cancer	0.000306	0.00311	CcSEcCtD
Pethidine—Hypertension—Epirubicin—bone cancer	0.000305	0.0031	CcSEcCtD
Pethidine—GRIN2D—Transmission across Chemical Synapses—BRAF—bone cancer	0.000304	0.00308	CbGpPWpGaD
Pethidine—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000303	0.00307	CbGpPWpGaD
Pethidine—Agitation—Doxorubicin—bone cancer	0.0003	0.00305	CcSEcCtD
Pethidine—Anxiety—Epirubicin—bone cancer	0.000299	0.00305	CcSEcCtD
Pethidine—OPRK1—GPCR ligand binding—GRM4—bone cancer	0.000299	0.00303	CbGpPWpGaD
Pethidine—CYP2C19—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000299	0.00303	CbGpPWpGaD
Pethidine—Hyperhidrosis—Methotrexate—bone cancer	0.000297	0.00303	CcSEcCtD
Pethidine—Dry mouth—Epirubicin—bone cancer	0.000294	0.00299	CcSEcCtD
Pethidine—Vertigo—Doxorubicin—bone cancer	0.000293	0.00299	CcSEcCtD
Pethidine—Anorexia—Methotrexate—bone cancer	0.000293	0.00299	CcSEcCtD
Pethidine—Syncope—Doxorubicin—bone cancer	0.000293	0.00298	CcSEcCtD
Pethidine—Confusional state—Epirubicin—bone cancer	0.00029	0.00296	CcSEcCtD
Pethidine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.00029	0.00293	CbGpPWpGaD
Pethidine—Palpitations—Doxorubicin—bone cancer	0.000288	0.00294	CcSEcCtD
Pethidine—Oedema—Epirubicin—bone cancer	0.000288	0.00293	CcSEcCtD
Pethidine—Anaphylactic shock—Epirubicin—bone cancer	0.000288	0.00293	CcSEcCtD
Pethidine—Hypotension—Methotrexate—bone cancer	0.000287	0.00293	CcSEcCtD
Pethidine—Loss of consciousness—Doxorubicin—bone cancer	0.000287	0.00292	CcSEcCtD
Pethidine—Shock—Epirubicin—bone cancer	0.000283	0.00288	CcSEcCtD
Pethidine—Convulsion—Doxorubicin—bone cancer	0.000283	0.00288	CcSEcCtD
Pethidine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—BRAF—bone cancer	0.000283	0.00286	CbGpPWpGaD
Pethidine—GRIN1—EPH-Ephrin signaling—MMP9—bone cancer	0.000283	0.00286	CbGpPWpGaD
Pethidine—SLC6A2—NRF2 pathway—TGFBR2—bone cancer	0.000282	0.00285	CbGpPWpGaD
Pethidine—SLC6A2—NRF2 pathway—GSTP1—bone cancer	0.000282	0.00285	CbGpPWpGaD
Pethidine—Hypertension—Doxorubicin—bone cancer	0.000282	0.00287	CcSEcCtD
Pethidine—Tachycardia—Epirubicin—bone cancer	0.000281	0.00286	CcSEcCtD
Pethidine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000279	0.00282	CbGpPWpGaD
Pethidine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000279	0.00282	CbGpPWpGaD
Pethidine—Hyperhidrosis—Epirubicin—bone cancer	0.000278	0.00283	CcSEcCtD
Pethidine—Insomnia—Methotrexate—bone cancer	0.000278	0.00283	CcSEcCtD
Pethidine—Anxiety—Doxorubicin—bone cancer	0.000277	0.00282	CcSEcCtD
Pethidine—GRIN2B—EPH-Ephrin signaling—MMP9—bone cancer	0.000276	0.00279	CbGpPWpGaD
Pethidine—CYP2D6—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000275	0.00278	CbGpPWpGaD
Pethidine—Anorexia—Epirubicin—bone cancer	0.000274	0.00279	CcSEcCtD
Pethidine—GRIN2C—Transmission across Chemical Synapses—MDM2—bone cancer	0.000274	0.00278	CbGpPWpGaD
Pethidine—Somnolence—Methotrexate—bone cancer	0.000273	0.00279	CcSEcCtD
Pethidine—Dry mouth—Doxorubicin—bone cancer	0.000272	0.00277	CcSEcCtD
Pethidine—Hypotension—Epirubicin—bone cancer	0.000269	0.00274	CcSEcCtD
Pethidine—GRIN1—Spinal Cord Injury—PTGS2—bone cancer	0.000269	0.00272	CbGpPWpGaD
Pethidine—Confusional state—Doxorubicin—bone cancer	0.000269	0.00274	CcSEcCtD
Pethidine—Decreased appetite—Methotrexate—bone cancer	0.000267	0.00272	CcSEcCtD
Pethidine—Anaphylactic shock—Doxorubicin—bone cancer	0.000266	0.00271	CcSEcCtD
Pethidine—Oedema—Doxorubicin—bone cancer	0.000266	0.00271	CcSEcCtD
Pethidine—Shock—Doxorubicin—bone cancer	0.000262	0.00267	CcSEcCtD
Pethidine—Insomnia—Epirubicin—bone cancer	0.00026	0.00265	CcSEcCtD
Pethidine—Tachycardia—Doxorubicin—bone cancer	0.00026	0.00265	CcSEcCtD
Pethidine—OPRK1—GPCR ligand binding—GRM1—bone cancer	0.000259	0.00262	CbGpPWpGaD
Pethidine—Hyperhidrosis—Doxorubicin—bone cancer	0.000258	0.00262	CcSEcCtD
Pethidine—Somnolence—Epirubicin—bone cancer	0.000256	0.00261	CcSEcCtD
Pethidine—GRIN2D—Transmission across Chemical Synapses—MDM2—bone cancer	0.000255	0.00258	CbGpPWpGaD
Pethidine—Anorexia—Doxorubicin—bone cancer	0.000254	0.00259	CcSEcCtD
Pethidine—Feeling abnormal—Methotrexate—bone cancer	0.000254	0.00258	CcSEcCtD
Pethidine—OPRM1—GPCR ligand binding—GRM4—bone cancer	0.000253	0.00256	CbGpPWpGaD
Pethidine—GRIN2A—Alzheimers Disease—TP53—bone cancer	0.000253	0.00256	CbGpPWpGaD
Pethidine—GRIN2C—Neuronal System—BRAF—bone cancer	0.000251	0.00254	CbGpPWpGaD
Pethidine—Decreased appetite—Epirubicin—bone cancer	0.00025	0.00255	CcSEcCtD
Pethidine—GRIN2A—Transmission across Chemical Synapses—BRAF—bone cancer	0.00025	0.00253	CbGpPWpGaD
Pethidine—SLC6A3—NRF2 pathway—TGFBR2—bone cancer	0.00025	0.00253	CbGpPWpGaD
Pethidine—SLC6A3—NRF2 pathway—GSTP1—bone cancer	0.00025	0.00253	CbGpPWpGaD
Pethidine—Hypotension—Doxorubicin—bone cancer	0.000249	0.00253	CcSEcCtD
Pethidine—Constipation—Epirubicin—bone cancer	0.000246	0.00251	CcSEcCtD
Pethidine—CYP2C19—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000246	0.00249	CbGpPWpGaD
Pethidine—Urticaria—Methotrexate—bone cancer	0.000244	0.00249	CcSEcCtD
Pethidine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000243	0.00246	CbGpPWpGaD
Pethidine—Insomnia—Doxorubicin—bone cancer	0.000241	0.00245	CcSEcCtD
Pethidine—Feeling abnormal—Epirubicin—bone cancer	0.000237	0.00242	CcSEcCtD
Pethidine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—MDM2—bone cancer	0.000237	0.0024	CbGpPWpGaD
Pethidine—Somnolence—Doxorubicin—bone cancer	0.000237	0.00241	CcSEcCtD
Pethidine—GRIN1—Spinal Cord Injury—MMP9—bone cancer	0.000236	0.00238	CbGpPWpGaD
Pethidine—GRIN2D—Neuronal System—BRAF—bone cancer	0.000233	0.00236	CbGpPWpGaD
Pethidine—Decreased appetite—Doxorubicin—bone cancer	0.000232	0.00236	CcSEcCtD
Pethidine—Urticaria—Epirubicin—bone cancer	0.000229	0.00233	CcSEcCtD
Pethidine—Constipation—Doxorubicin—bone cancer	0.000228	0.00232	CcSEcCtD
Pethidine—Hypersensitivity—Methotrexate—bone cancer	0.000227	0.00231	CcSEcCtD
Pethidine—CYP2D6—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.000226	0.00229	CbGpPWpGaD
Pethidine—SLC6A2—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000222	0.00224	CbGpPWpGaD
Pethidine—Asthenia—Methotrexate—bone cancer	0.000221	0.00225	CcSEcCtD
Pethidine—GRIN1—Alzheimers Disease—TP53—bone cancer	0.00022	0.00223	CbGpPWpGaD
Pethidine—Feeling abnormal—Doxorubicin—bone cancer	0.00022	0.00224	CcSEcCtD
Pethidine—OPRM1—GPCR ligand binding—GRM1—bone cancer	0.000219	0.00222	CbGpPWpGaD
Pethidine—GRIN1—Transmission across Chemical Synapses—BRAF—bone cancer	0.000218	0.00221	CbGpPWpGaD
Pethidine—Pruritus—Methotrexate—bone cancer	0.000218	0.00222	CcSEcCtD
Pethidine—GRIN2B—Alzheimers Disease—TP53—bone cancer	0.000215	0.00217	CbGpPWpGaD
Pethidine—GRIN2B—Transmission across Chemical Synapses—BRAF—bone cancer	0.000213	0.00215	CbGpPWpGaD
Pethidine—Hypersensitivity—Epirubicin—bone cancer	0.000212	0.00216	CcSEcCtD
Pethidine—Urticaria—Doxorubicin—bone cancer	0.000212	0.00216	CcSEcCtD
Pethidine—GRIN2C—Neuronal System—MDM2—bone cancer	0.00021	0.00213	CbGpPWpGaD
Pethidine—GRIN2A—Transmission across Chemical Synapses—MDM2—bone cancer	0.000209	0.00212	CbGpPWpGaD
Pethidine—Asthenia—Epirubicin—bone cancer	0.000207	0.0021	CcSEcCtD
Pethidine—GRIN1—BDNF signaling pathway—JUN—bone cancer	0.000207	0.00209	CbGpPWpGaD
Pethidine—Pruritus—Epirubicin—bone cancer	0.000204	0.00207	CcSEcCtD
Pethidine—Dizziness—Methotrexate—bone cancer	0.000203	0.00207	CcSEcCtD
Pethidine—GRIN2B—BDNF signaling pathway—JUN—bone cancer	0.000201	0.00204	CbGpPWpGaD
Pethidine—SLC6A3—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000196	0.00199	CbGpPWpGaD
Pethidine—Hypersensitivity—Doxorubicin—bone cancer	0.000196	0.002	CcSEcCtD
Pethidine—Vomiting—Methotrexate—bone cancer	0.000196	0.00199	CcSEcCtD
Pethidine—GRIN2D—Neuronal System—MDM2—bone cancer	0.000195	0.00198	CbGpPWpGaD
Pethidine—Rash—Methotrexate—bone cancer	0.000194	0.00198	CcSEcCtD
Pethidine—Dermatitis—Methotrexate—bone cancer	0.000194	0.00197	CcSEcCtD
Pethidine—GRIN1—SIDS Susceptibility Pathways—JUN—bone cancer	0.000194	0.00196	CbGpPWpGaD
Pethidine—Headache—Methotrexate—bone cancer	0.000193	0.00196	CcSEcCtD
Pethidine—GRIN2A—Neuronal System—BRAF—bone cancer	0.000192	0.00194	CbGpPWpGaD
Pethidine—SLC6A2—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.000191	0.00194	CbGpPWpGaD
Pethidine—Asthenia—Doxorubicin—bone cancer	0.000191	0.00195	CcSEcCtD
Pethidine—GRIN1—Spinal Cord Injury—EGFR—bone cancer	0.00019	0.00193	CbGpPWpGaD
Pethidine—Dizziness—Epirubicin—bone cancer	0.00019	0.00194	CcSEcCtD
Pethidine—Pruritus—Doxorubicin—bone cancer	0.000188	0.00192	CcSEcCtD
Pethidine—SLC6A4—Circadian rythm related genes—CDK4—bone cancer	0.000184	0.00186	CbGpPWpGaD
Pethidine—Vomiting—Epirubicin—bone cancer	0.000183	0.00186	CcSEcCtD
Pethidine—OPRK1—GPCR ligand binding—SMO—bone cancer	0.000183	0.00185	CbGpPWpGaD
Pethidine—Nausea—Methotrexate—bone cancer	0.000183	0.00186	CcSEcCtD
Pethidine—GRIN1—Transmission across Chemical Synapses—MDM2—bone cancer	0.000183	0.00185	CbGpPWpGaD
Pethidine—OPRM1—TCR Signaling Pathway—JUN—bone cancer	0.000182	0.00184	CbGpPWpGaD
Pethidine—Rash—Epirubicin—bone cancer	0.000182	0.00185	CcSEcCtD
Pethidine—Dermatitis—Epirubicin—bone cancer	0.000181	0.00185	CcSEcCtD
Pethidine—Headache—Epirubicin—bone cancer	0.00018	0.00184	CcSEcCtD
Pethidine—GRIN2B—Transmission across Chemical Synapses—MDM2—bone cancer	0.000178	0.0018	CbGpPWpGaD
Pethidine—Dizziness—Doxorubicin—bone cancer	0.000176	0.00179	CcSEcCtD
Pethidine—CYP2B6—Biological oxidations—CYP3A4—bone cancer	0.000173	0.00175	CbGpPWpGaD
Pethidine—Nausea—Epirubicin—bone cancer	0.000171	0.00174	CcSEcCtD
Pethidine—CYP2B6—Metapathway biotransformation—CYP3A4—bone cancer	0.00017	0.00172	CbGpPWpGaD
Pethidine—SLC6A3—Transmembrane transport of small molecules—TUBB2A—bone cancer	0.00017	0.00172	CbGpPWpGaD
Pethidine—Vomiting—Doxorubicin—bone cancer	0.000169	0.00172	CcSEcCtD
Pethidine—OPRK1—GPCR downstream signaling—RGS1—bone cancer	0.000169	0.00171	CbGpPWpGaD
Pethidine—OPRK1—GPCR downstream signaling—GRM4—bone cancer	0.000169	0.00171	CbGpPWpGaD
Pethidine—Rash—Doxorubicin—bone cancer	0.000168	0.00171	CcSEcCtD
Pethidine—Dermatitis—Doxorubicin—bone cancer	0.000168	0.00171	CcSEcCtD
Pethidine—GRIN1—Axon guidance—MET—bone cancer	0.000168	0.0017	CbGpPWpGaD
Pethidine—GRIN1—Neuronal System—BRAF—bone cancer	0.000167	0.00169	CbGpPWpGaD
Pethidine—Headache—Doxorubicin—bone cancer	0.000167	0.0017	CcSEcCtD
Pethidine—GRIN2B—Axon guidance—MET—bone cancer	0.000163	0.00165	CbGpPWpGaD
Pethidine—GRIN2B—Neuronal System—BRAF—bone cancer	0.000163	0.00165	CbGpPWpGaD
Pethidine—GRIN2A—Neuronal System—MDM2—bone cancer	0.00016	0.00162	CbGpPWpGaD
Pethidine—GRIN1—Spinal Cord Injury—TP53—bone cancer	0.00016	0.00162	CbGpPWpGaD
Pethidine—Nausea—Doxorubicin—bone cancer	0.000158	0.00161	CcSEcCtD
Pethidine—CYP2C19—Arachidonic acid metabolism—PTGS2—bone cancer	0.000155	0.00157	CbGpPWpGaD
Pethidine—OPRM1—GPCR ligand binding—SMO—bone cancer	0.000154	0.00156	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—RGS1—bone cancer	0.000154	0.00155	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—GRM4—bone cancer	0.000154	0.00155	CbGpPWpGaD
Pethidine—CYP2B6—Biological oxidations—GSTP1—bone cancer	0.000148	0.00149	CbGpPWpGaD
Pethidine—OPRK1—GPCR downstream signaling—GRM1—bone cancer	0.000147	0.00148	CbGpPWpGaD
Pethidine—CYP2B6—Metapathway biotransformation—GSTP1—bone cancer	0.000146	0.00147	CbGpPWpGaD
Pethidine—SLC6A4—SIDS Susceptibility Pathways—JUN—bone cancer	0.000145	0.00147	CbGpPWpGaD
Pethidine—ALB—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000143	0.00145	CbGpPWpGaD
Pethidine—OPRM1—GPCR downstream signaling—RGS1—bone cancer	0.000143	0.00145	CbGpPWpGaD
Pethidine—OPRM1—GPCR downstream signaling—GRM4—bone cancer	0.000143	0.00145	CbGpPWpGaD
Pethidine—GRIN1—Neuronal System—MDM2—bone cancer	0.00014	0.00142	CbGpPWpGaD
Pethidine—GRIN1—Axon guidance—MMP2—bone cancer	0.00014	0.00141	CbGpPWpGaD
Pethidine—GRIN2B—Neuronal System—MDM2—bone cancer	0.000136	0.00138	CbGpPWpGaD
Pethidine—GRIN2B—Axon guidance—MMP2—bone cancer	0.000136	0.00138	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—GRM1—bone cancer	0.000133	0.00135	CbGpPWpGaD
Pethidine—ALB—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000131	0.00133	CbGpPWpGaD
Pethidine—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.00013	0.00132	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—GRM4—bone cancer	0.00013	0.00131	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—RGS1—bone cancer	0.00013	0.00131	CbGpPWpGaD
Pethidine—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000129	0.0013	CbGpPWpGaD
Pethidine—SLC6A3—Transmission across Chemical Synapses—BRAF—bone cancer	0.000125	0.00126	CbGpPWpGaD
Pethidine—OPRM1—GPCR downstream signaling—GRM1—bone cancer	0.000124	0.00125	CbGpPWpGaD
Pethidine—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.00012	0.00121	CbGpPWpGaD
Pethidine—GRIN1—Developmental Biology—CDK4—bone cancer	0.00012	0.00121	CbGpPWpGaD
Pethidine—GRIN1—Developmental Biology—MET—bone cancer	0.00012	0.00121	CbGpPWpGaD
Pethidine—ALB—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000119	0.0012	CbGpPWpGaD
Pethidine—SLC6A4—Circadian rythm related genes—JUN—bone cancer	0.000119	0.0012	CbGpPWpGaD
Pethidine—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	0.000118	0.0012	CbGpPWpGaD
Pethidine—GRIN2B—Developmental Biology—CDK4—bone cancer	0.000117	0.00118	CbGpPWpGaD
Pethidine—GRIN2B—Developmental Biology—MET—bone cancer	0.000117	0.00118	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—GRM1—bone cancer	0.000112	0.00114	CbGpPWpGaD
Pethidine—CYP2C19—Biological oxidations—GSTP1—bone cancer	0.000112	0.00113	CbGpPWpGaD
Pethidine—ALB—Transmembrane transport of small molecules—TUBB4B—bone cancer	0.000111	0.00113	CbGpPWpGaD
Pethidine—ALB—Selenium Micronutrient Network—PTGS2—bone cancer	0.00011	0.00111	CbGpPWpGaD
Pethidine—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	0.00011	0.00111	CbGpPWpGaD
Pethidine—GRIN1—Axon guidance—MMP9—bone cancer	0.000105	0.00106	CbGpPWpGaD
Pethidine—SLC6A3—Transmission across Chemical Synapses—MDM2—bone cancer	0.000104	0.00106	CbGpPWpGaD
Pethidine—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	0.000104	0.00105	CbGpPWpGaD
Pethidine—CYP2B6—Metabolism—NDUFA12—bone cancer	0.000104	0.00105	CbGpPWpGaD
Pethidine—CYP2D6—Biological oxidations—GSTP1—bone cancer	0.000103	0.00104	CbGpPWpGaD
Pethidine—GRIN2B—Axon guidance—MMP9—bone cancer	0.000102	0.00104	CbGpPWpGaD
Pethidine—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	0.000101	0.00102	CbGpPWpGaD
Pethidine—GRIN1—Developmental Biology—MMP2—bone cancer	9.97e-05	0.00101	CbGpPWpGaD
Pethidine—GRIN2B—Developmental Biology—MMP2—bone cancer	9.72e-05	0.000984	CbGpPWpGaD
Pethidine—ALB—Transmembrane transport of small molecules—TUBB2A—bone cancer	9.62e-05	0.000973	CbGpPWpGaD
Pethidine—SLC6A3—Neuronal System—BRAF—bone cancer	9.55e-05	0.000966	CbGpPWpGaD
Pethidine—OPRK1—GPCR downstream signaling—GNA11—bone cancer	9.45e-05	0.000956	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—SMO—bone cancer	9.38e-05	0.000949	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—GRM4—bone cancer	9.07e-05	0.000918	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—RGS1—bone cancer	9.07e-05	0.000918	CbGpPWpGaD
Pethidine—ALB—Metabolism—NDUFA12—bone cancer	8.71e-05	0.000882	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—GNA11—bone cancer	8.58e-05	0.000868	CbGpPWpGaD
Pethidine—CYP2B6—Metabolism—NT5C3A—bone cancer	8.58e-05	0.000868	CbGpPWpGaD
Pethidine—OPRK1—GPCR downstream signaling—IL3—bone cancer	8.56e-05	0.000866	CbGpPWpGaD
Pethidine—GRIN1—Axon guidance—EGFR—bone cancer	8.49e-05	0.000859	CbGpPWpGaD
Pethidine—GRIN2B—Axon guidance—EGFR—bone cancer	8.27e-05	0.000837	CbGpPWpGaD
Pethidine—ALB—Folate Metabolism—TP53—bone cancer	8.25e-05	0.000835	CbGpPWpGaD
Pethidine—SLC6A3—Neuronal System—MDM2—bone cancer	8e-05	0.000809	CbGpPWpGaD
Pethidine—OPRM1—GPCR downstream signaling—GNA11—bone cancer	7.98e-05	0.000808	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—SMO—bone cancer	7.93e-05	0.000802	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—GRM1—bone cancer	7.86e-05	0.000796	CbGpPWpGaD
Pethidine—SLC6A4—Circadian rythm related genes—TP53—bone cancer	7.83e-05	0.000792	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism—NDUFA12—bone cancer	7.82e-05	0.000791	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—IL3—bone cancer	7.78e-05	0.000787	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—GRM4—bone cancer	7.66e-05	0.000776	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—RGS1—bone cancer	7.66e-05	0.000776	CbGpPWpGaD
Pethidine—GRIN1—Developmental Biology—MMP9—bone cancer	7.49e-05	0.000758	CbGpPWpGaD
Pethidine—ALB—Hemostasis—SPARC—bone cancer	7.39e-05	0.000748	CbGpPWpGaD
Pethidine—GRIN2B—Developmental Biology—MMP9—bone cancer	7.31e-05	0.000739	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—GNA11—bone cancer	7.25e-05	0.000733	CbGpPWpGaD
Pethidine—OPRM1—GPCR downstream signaling—IL3—bone cancer	7.24e-05	0.000732	CbGpPWpGaD
Pethidine—ALB—Metabolism—NT5C3A—bone cancer	7.22e-05	0.000731	CbGpPWpGaD
Pethidine—CYP2D6—Metabolism—NDUFA12—bone cancer	7.19e-05	0.000728	CbGpPWpGaD
Pethidine—ALB—Hemostasis—GNA11—bone cancer	6.76e-05	0.000684	CbGpPWpGaD
Pethidine—CYP3A4—Biological oxidations—GSTP1—bone cancer	6.71e-05	0.000679	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—GRM1—bone cancer	6.65e-05	0.000672	CbGpPWpGaD
Pethidine—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	6.62e-05	0.00067	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—IL3—bone cancer	6.57e-05	0.000665	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism—NT5C3A—bone cancer	6.48e-05	0.000656	CbGpPWpGaD
Pethidine—ALB—Hemostasis—IL3—bone cancer	6.13e-05	0.00062	CbGpPWpGaD
Pethidine—GRIN1—Developmental Biology—EGFR—bone cancer	6.06e-05	0.000613	CbGpPWpGaD
Pethidine—CYP2D6—Metabolism—NT5C3A—bone cancer	5.96e-05	0.000603	CbGpPWpGaD
Pethidine—GRIN2B—Developmental Biology—EGFR—bone cancer	5.9e-05	0.000597	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—SMO—bone cancer	5.54e-05	0.000561	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—GNA11—bone cancer	5.07e-05	0.000513	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—ATF1—bone cancer	4.71e-05	0.000477	CbGpPWpGaD
Pethidine—CYP3A4—Metabolism—NDUFA12—bone cancer	4.7e-05	0.000476	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—SMO—bone cancer	4.68e-05	0.000474	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—IL3—bone cancer	4.59e-05	0.000465	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—GNA11—bone cancer	4.28e-05	0.000433	CbGpPWpGaD
Pethidine—ALB—Hemostasis—PLAU—bone cancer	4.02e-05	0.000407	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—ATF1—bone cancer	3.98e-05	0.000403	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—TGFBR2—bone cancer	3.93e-05	0.000398	CbGpPWpGaD
Pethidine—CYP3A4—Metabolism—NT5C3A—bone cancer	3.9e-05	0.000394	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—IL3—bone cancer	3.88e-05	0.000393	CbGpPWpGaD
Pethidine—CYP2B6—Metabolism—ENO2—bone cancer	3.76e-05	0.00038	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—IGF1R—bone cancer	3.7e-05	0.000374	CbGpPWpGaD
Pethidine—CYP2B6—Metabolism—DHFR—bone cancer	3.49e-05	0.000353	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—TGFBR2—bone cancer	3.32e-05	0.000336	CbGpPWpGaD
Pethidine—CYP2B6—Metabolism—GNA11—bone cancer	3.26e-05	0.00033	CbGpPWpGaD
Pethidine—ALB—Metabolism—ENO2—bone cancer	3.16e-05	0.00032	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—IGF1R—bone cancer	3.12e-05	0.000316	CbGpPWpGaD
Pethidine—CYP2B6—Metabolism—CYP3A4—bone cancer	2.95e-05	0.000299	CbGpPWpGaD
Pethidine—ALB—Metabolism—DHFR—bone cancer	2.93e-05	0.000297	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism—ENO2—bone cancer	2.84e-05	0.000287	CbGpPWpGaD
Pethidine—ALB—Metabolism—GNA11—bone cancer	2.74e-05	0.000277	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—KIT—bone cancer	2.68e-05	0.000271	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism—DHFR—bone cancer	2.63e-05	0.000266	CbGpPWpGaD
Pethidine—CYP2D6—Metabolism—ENO2—bone cancer	2.61e-05	0.000264	CbGpPWpGaD
Pethidine—CYP2B6—Metabolism—GSTP1—bone cancer	2.53e-05	0.000256	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—BRAF—bone cancer	2.52e-05	0.000255	CbGpPWpGaD
Pethidine—ALB—Metabolism—CYP3A4—bone cancer	2.49e-05	0.000252	CbGpPWpGaD
Pethidine—ALB—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.47e-05	0.00025	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism—GNA11—bone cancer	2.46e-05	0.000249	CbGpPWpGaD
Pethidine—OPRK1—Signaling by GPCR—EGFR—bone cancer	2.44e-05	0.000247	CbGpPWpGaD
Pethidine—CYP2D6—Metabolism—DHFR—bone cancer	2.42e-05	0.000245	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—KIT—bone cancer	2.27e-05	0.000229	CbGpPWpGaD
Pethidine—CYP2D6—Metabolism—GNA11—bone cancer	2.26e-05	0.000229	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism—CYP3A4—bone cancer	2.23e-05	0.000226	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.22e-05	0.000225	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—BRAF—bone cancer	2.13e-05	0.000215	CbGpPWpGaD
Pethidine—ALB—Metabolism—GSTP1—bone cancer	2.13e-05	0.000215	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—MDM2—bone cancer	2.11e-05	0.000214	CbGpPWpGaD
Pethidine—OPRM1—Signaling by GPCR—EGFR—bone cancer	2.06e-05	0.000209	CbGpPWpGaD
Pethidine—CYP2D6—Metabolism—CYP3A4—bone cancer	2.05e-05	0.000208	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism—GSTP1—bone cancer	1.91e-05	0.000193	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—JUN—bone cancer	1.84e-05	0.000186	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—MMP9—bone cancer	1.79e-05	0.000181	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—MDM2—bone cancer	1.78e-05	0.000181	CbGpPWpGaD
Pethidine—CYP2D6—Metabolism—GSTP1—bone cancer	1.76e-05	0.000178	CbGpPWpGaD
Pethidine—CYP3A4—Metabolism—ENO2—bone cancer	1.71e-05	0.000173	CbGpPWpGaD
Pethidine—ALB—Hemostasis—TP53—bone cancer	1.62e-05	0.000164	CbGpPWpGaD
Pethidine—CYP3A4—Metabolism—DHFR—bone cancer	1.58e-05	0.00016	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—JUN—bone cancer	1.55e-05	0.000157	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—MMP9—bone cancer	1.51e-05	0.000153	CbGpPWpGaD
Pethidine—CYP3A4—Metabolism—GNA11—bone cancer	1.48e-05	0.00015	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—EGFR—bone cancer	1.44e-05	0.000146	CbGpPWpGaD
Pethidine—CYP2B6—Metabolism—PTGS2—bone cancer	1.31e-05	0.000132	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—EGFR—bone cancer	1.22e-05	0.000123	CbGpPWpGaD
Pethidine—OPRK1—Signaling Pathways—TP53—bone cancer	1.21e-05	0.000123	CbGpPWpGaD
Pethidine—CYP3A4—Metabolism—GSTP1—bone cancer	1.15e-05	0.000116	CbGpPWpGaD
Pethidine—ALB—Metabolism—PTGS2—bone cancer	1.1e-05	0.000111	CbGpPWpGaD
Pethidine—OPRM1—Signaling Pathways—TP53—bone cancer	1.02e-05	0.000104	CbGpPWpGaD
Pethidine—CYP2C19—Metabolism—PTGS2—bone cancer	9.89e-06	0.0001	CbGpPWpGaD
Pethidine—CYP2D6—Metabolism—PTGS2—bone cancer	9.09e-06	9.2e-05	CbGpPWpGaD
Pethidine—CYP3A4—Metabolism—PTGS2—bone cancer	5.95e-06	6.02e-05	CbGpPWpGaD
